T1	intervention 0 27	Ribociclib plus fulvestrant
T2	outcome 2033 2036	mOS
T3	iv-cont-median 2041 2052	39.7 months
T4	cv-cont-median 2073 2084	33.7 months
T7	outcome 1936 1939	mOS
T8	cv-cont-median 1944 1955	51.8 months
T11	outcome 1630 1645	median OS (mOS)
T12	iv-cont-median 1650 1661	53.7 months
T13	cv-cont-median 1682 1693	41.5 months
T17	total-participants 1526 1529	726
T18	intervention-participants 1563 1566	484
T19	control-participants 1580 1583	242
T20	outcome-Measure 1371 1373	OS
T21	control 1249 1256	placebo
T5	eligibility 782 884	men and postmenopausal women (age â‰¥18 years) with histologically/cytologically confirmed HR+/HER2- ABC
